Article: Spectrum Deals For Rights To Clinical-Stage LHRH Antagonist.

Article from:
BIOWORLD Today
Article date:
November 3, 2009
Copyright

Senior Staff Writer

Finding itself in the right place at the right time, Spectrum Pharmaceuticals Inc. gained access to a Phase II product for hormone-dependent cancers, such as prostate cancer, and benign but proliferative disorders such as benign prostatic hypertrophy and endometriosis.

The Irvine, Calif.-based company, which primarily is focused on oncology, acquired an exclusive license from AEterna Zentaris Inc. to develop and commercialize D-63153 for all indications in North America and India. AEterna Zentaris retains exclusive rights in the rest of world.

Its German subsidiary, Zentaris GmbH, out-licensed the product following the ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: AEterna Zentaris Enters a License and Collaboration ...
PR Newswire;  August 12, 2004 ;     700+ words ... ... generation LHRH antagonist D-63153 ... the heels of AEterna Zentaris regaining ... Zentaris Inc. AEterna Zentaris Inc. is a ... cetrorelix, an LHRH antagonist already marketed ... BPH). AEterna Zentaris also owns ...

Article: AEterna Zentaris Regains Exclusive Worldwide ...
PR Newswire;  May 8, 2007 ;     700+ words ... ... immediately. AEterna Zentaris has regained exclusive ... Releasing Hormone (LHRH) antagonist, cetrorelix in ... priority for Solvay. AEterna Zentaris will conduct a ... Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach ...

Article: AEterna Zentaris' Partner, Spectrum, Provides ...
PR Newswire;  April 22, 2008 ;     700+ words ... ... FirstCall/ -- AEterna Zentaris Inc. (NASDAQ ... hormone (LHRH) antagonist in benign ... generation LHRH antagonist administered ... August 2004, AEterna Zentaris granted Spectrum ... is part of AEterna Zentaris' LHRH antagonist therapeutic ...

Article: AEterna Zentaris Reports Positive Results with ...
PR Newswire;  March 22, 2007 ;     700+ words ... ... FirstCall/ -- AEterna Zentaris Inc. (TSX ... releasing hormone (LHRH) antagonist, was safe and ... most advanced LHRH antagonist in development ... Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach ...

Article: AEterna Zentaris: Article on Phase 2 Trial with ...
PR Newswire;  May 13, 2008 ;     700+ words ... ... FirstCall/ -- AEterna Zentaris Inc. , a global ... subcutaneously administered LHRH antagonist cetrorelix in ... Scientific Affairs at AEterna Zentaris commented ... Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach ...

Article: AEterna Zentaris Completes Patient Recruitment for ...
PR Newswire;  December 11, 2008 ;     700+ words ... ... FirstCall/ -- AEterna Zentaris Inc. (NASDAQ ... releasing hormone (LHRH) antagonist. This safety ... Medical Officer at AEterna Zentaris. "Furthermore ... Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach ...

Article: AEterna Zentaris: Lead Investigator for Cetrorelix ...
PR Newswire;  April 30, 2008 ;     700+ words ... ... FirstCall/ -- AEterna Zentaris Inc. , a global ... Italy. Titled "LHRH antagonist cetrorelix for ... Scientific Affairs at AEterna Zentaris commented ... Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach ...

Article: AEterna Zentaris Initiates First Study of Phase 3 ...
PR Newswire;  January 8, 2007 ;     700+ words ... ... FirstCall/ -- AEterna Zentaris Inc. (TSX ... releasing hormone (LHRH) antagonist compound, cetrorelix ... most advanced LHRH-antagonist in development ... Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives